Get to know our clinical trials
Patients with metastatic breast cancer
THE MAIN OBJECTIVE OF THIS STUDY IS TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY (HOW WELL A DRUG WORKS) OF SAMURACICLIB IN COMBINATION WITH ELACESTRANT FOR THE TREATMENT OF HR AND HER2- BREAST CANCER.
Technical Summary
- PHASE IB/II OPEN-LABEL STUDY OF SAMURACICLIB IN COMBINATION WITH ELACESTRANT IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE METASTATIC OR LOCALLY ADVANCED BREAST CANCER.
- Code EudraCT: 2023-000072-35
- Protocol number: CT7001-003
- Promoter: Carrick Therapeutics
- Molecule/Drug: Samuraciclib
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.